Amgen's Repatha beats sales estimates in 2Q17

Amgen Inc. (NASDAQ:AMGN) reported 2Q17 earnings that topped estimates, including sales of hypercholesterolemia drug Repatha evolocumab that exceeded expectations.

Repatha's sales rose to $83 million, up sequentially from $49 million in 1Q17 and ahead of a consensus $74.5 million estimate. Sales of the PCSK9 inhibitor increased roughly threefold from $27 million in 2Q16. FDA approved the drug in August 2015...